Hikal posts FY23 PAT at Rs. 36 Cr
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Continues to Expand its Presence in South India
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
Subscribe To Our Newsletter & Stay Updated